PMID- 10770416
OWN - NLM
STAT- MEDLINE
DCOM- 20000601
LR  - 20191103
IS  - 0902-0063 (Print)
IS  - 0902-0063 (Linking)
VI  - 14
IP  - 2
DP  - 2000 Apr
TI  - Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone 
      marrow transplant patients.
PG  - 121-6
AB  - Mycophenolate mofetil (MMF), a new immunosuppressive drug successfully used in 
      renal and heart transplant recipients, was used in combination with cyclosporin A 
      (CsA), methotrexate (MTX) and prednisolone for the prophylaxis of acute 
      graft-versus-host disease (aGVHD) after bone marrow transplantation (BMT) and 
      peripheral blood stem cell transplantation (PBSCT) from human leukocyte antigen 
      (HLA)-mismatched, unrelated (n = 9) and related donors (n = 4) in an open 
      single-centre phase II study. Thirteen patients, transplanted from HLA-mismatched 
      donors of 18-57 yr of age, received 1 g MMF daily, starting at day 10, in 
      addition to CsA and prednisolone for aGVHD prophylaxis. All patients were 
      engrafted between days 13 and 15. Four of the 13 patients experienced aGVHD grade 
      I/II (n = 2) and grade III (n = 2). All patients except 3 were alive on day 100 
      post-transplantation. No severe adverse effects of MMF were recorded. In our 
      pilot study, we demonstrated that MMF can be used safely for the prophylaxis of 
      aGVHD.
FAU - Basara, N
AU  - Basara N
AD  - Clinic for Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, 
      Germany. office@bmt-center-io.com
FAU - Blau, W I
AU  - Blau WI
FAU - Kiehl, M G
AU  - Kiehl MG
FAU - Schmetzer, B
AU  - Schmetzer B
FAU - Bischoff, M
AU  - Bischoff M
FAU - Kirsten, D
AU  - Kirsten D
FAU - Gunzelmann, S
AU  - Gunzelmann S
FAU - Fauser, A A
AU  - Fauser AA
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - 0 (Drug Combinations)
RN  - 0 (Glucocorticoids)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Bone Marrow Transplantation/immunology
MH  - Cyclosporine/administration & dosage/therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Glucocorticoids/administration & dosage/therapeutic use
MH  - Graft vs Host Disease/*prevention & control
MH  - HLA Antigens/*analysis
MH  - Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility/*immunology
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Methotrexate/administration & dosage/therapeutic use
MH  - Middle Aged
MH  - Mycophenolic Acid/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Pilot Projects
MH  - Prednisolone/administration & dosage/therapeutic use
MH  - Safety
MH  - Survival Rate
MH  - Tissue Donors
EDAT- 2000/04/19 09:00
MHDA- 2000/06/03 09:00
CRDT- 2000/04/19 09:00
PHST- 2000/04/19 09:00 [pubmed]
PHST- 2000/06/03 09:00 [medline]
PHST- 2000/04/19 09:00 [entrez]
AID - 10.1034/j.1399-0012.2000.140204.x [doi]
PST - ppublish
SO  - Clin Transplant. 2000 Apr;14(2):121-6. doi: 10.1034/j.1399-0012.2000.140204.x.